Transgene

Contact
transgene.fr
+33388279100

Transgene SA

400, Boulevard Gonthier d'Andernach
67405 Illkirch Graffenstaden
France
+33388279100
transgene.fr
Contact
Profile Products News
Contact

About Transgene

Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has one product which has completed Phase II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing.

Read more about Transgene
Facts about Transgene
  • Founding: 1979
  • Focus : Manufacturer
  • Employees: 201-500
  • Industry : Biotechnology, Pharma

Product portfolio of Transgene

Product portfolio

Show all

Similar companies

Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies
Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies

News about Transgene

Transgene

13-Jul-2010 | research and development

Transgene Announces Opening of First Clinical Site for its Phase II Trial of TG4040 for the Treatment of Chronic Hepatitis C

Transgene S.A. announced the opening of the first clinical site for the phase II trial (named HCVac) of TG4040 (MVA-HCV) for the treatment of naïve ...

Read news
Transgene

04-Dec-2009 | research and development

Transgene Receives FDA Fast Track Status for TG4010 for Treatment of Non-Small Cell Lung Cancer

Transgene announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track development designation to its immunotherapy product TG4010 (MVA ...

Read news
Transgene

11-Jun-2009 | research and development

Transgene: FDA gives green light to Phase II trial with TG4010 targeted immunotherapy in lung cancer

Transgene announced that it recently met with the U.S. Food and Drug Administration (FDA) for an end of Phase II meeting when results of its TG4010 ...

Read news
Transgene

27-Apr-2009 | research and development

Transgene presents additional Phase I data for TG4040 in Hepatitis C chronically infected patients

Transgene S.A. announced additional interim results from its ongoing Phase I clinical study of its therapeutic vaccine TG4040 (MVA-HCV) conducted in ...

Read news
Transgene

05-Jun-2008 | research and development

Transgene announces promising Phase I preliminary results of its HCV therapeutic vaccine

Preliminary analysis demonstrates a favourable safety profile and shows antiviral activity of TG4040 on chronically infected treatment-naïve patients

Read news
Transgene

22-May-2008 | research and development

Transgene announces promising phase I preliminary results of its HCV therapeutic vaccine

Preliminary analysis demonstrates a favourable safety profile and shows antiviral activity of TG4040 on chronically infected treatment-naïve patients

Read news
Transgene

14-Jan-2008 | research and development

Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIbData in Advanced Non-Small Cell Lung Cancer

Transgene announced promising preliminary data from the Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first ...

Read news
Transgene

05-Jun-2007 | research and development

Transgene to Receive First Milestone Payment from Roche Following FDA and EMEA Review of TG 4001 (R3484) Phase III Studies Plan

Transgene S.A. announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) have reviewed the proposed plan to ...

Read news
Show more news about Transgene

Here you will find Transgene SA